| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.069 | 0.1 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.042 | 0.4 |